Initial findings of the AASK: African Americans with hypertensive kidney disease benefit from an ACE inhibitor

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 4, 2003, Pages 304-312

  Rahman, Mahboob ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST OF ILLNESS; DRUG EFFICACY; ENZYME INHIBITION; ETHNOLOGY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEGRO; NEPHROSCLEROSIS; PROTEINURIA; RACE DIFFERENCE; RENOVASCULAR HYPERTENSION; RISK BENEFIT ANALYSIS; SUSTAINED RELEASE FORMULATION;

EID: 0037738903     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.4.304     Document Type: Article

References (4)

1. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285:2719-2728.
2. US Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
3. Papademetriou V. Selection of anti hypertensive therapy for patients with hypertensive renal disease [editorial]. JAMA 2001; 285:2774-2776.
4. Rahman M, Douglas JG, Wright JT Jr. Pathophysiology and treatment implications of hypertension in the African American population. Endocrinol Metab Clin North Am 1997; 26:125-144.